Co-Authors
This is a "connection" page, showing publications co-authored by Philip Dormitzer and Ugur Sahin.
Connection Strength
1.623
-
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021 07; 595(7868):572-577.
Score: 0.237
-
Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2021 Feb; 590(7844):E17.
Score: 0.232
-
BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021 04; 592(7853):283-289.
Score: 0.232
-
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science. 2021 03 12; 371(6534):1152-1153.
Score: 0.232
-
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020 10; 586(7830):594-599.
Score: 0.226
-
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021 08; 596(7871):273-275.
Score: 0.059
-
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021 07 15; 385(3):239-250.
Score: 0.059
-
BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. N Engl J Med. 2021 07 29; 385(5):472-474.
Score: 0.059
-
Neutralizing Activity of BNT162b2-Elicited Serum. N Engl J Med. 2021 04 15; 384(15):1466-1468.
Score: 0.058
-
Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2021 Feb; 590(7844):E26.
Score: 0.058
-
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 12 31; 383(27):2603-2615.
Score: 0.057
-
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020 12 17; 383(25):2439-2450.
Score: 0.057
-
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020 10; 586(7830):589-593.
Score: 0.056